Harvard Bioscience (HBIO) Other Non-Current Assets (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Other Non-Current Assets of $2.6 million for Q1 2026, down 26.59% year-over-year from $3.5 million in Q1 2025, and down 3.98% quarter-over-quarter from $2.7 million in Q4 2025.
Harvard Bioscience (HBIO) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Other Non-Current Assets for 17 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 26.59% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (down 26.59% YoY), while the FY2025 annual figure was $2.7 million, down 5.08% from the prior year.
- Other Non-Current Assets eased to $2.6 million in Q1 2026 per HBIO's latest filing, from $2.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $8.7 million in Q2 2022 and bottomed at $2.6 million in Q1 2026.
- Historically, Other Non-Current Assets has averaged $5.2 million across 5 years, with a median of $4.8 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 1047.24% — and 2024, when it tumbled 61.08%.
- Harvard Bioscience's Other Non-Current Assets stood at $7.8 million in 2022, then retreated by 16.8% to $6.5 million in 2023, then plunged by 56.23% to $2.8 million in 2024, then declined by 5.08% to $2.7 million in 2025, then retreated by 3.98% to $2.6 million in 2026.
- Business Quant data shows HBIO's Other Non-Current Assets at $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 2.55 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 434.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 457.39 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 22.91 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 82.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 904.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 672.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 669.00 Mn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn | 2.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.53 Mn |
| Mar 31, 2026 | 2.58 Mn |
| Dec 31, 2025 | 2.69 Mn |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 3.79 Mn |
| Mar 31, 2025 | 3.52 Mn |
| Dec 31, 2024 | 2.83 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 4.79 Mn |
| Dec 31, 2023 | 6.47 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 6.41 Mn |
| Mar 31, 2023 | 7.94 Mn |
| Dec 31, 2022 | 7.78 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | 8.69 Mn |
| Mar 31, 2022 | 5.26 Mn |
| Dec 31, 2021 | 5.38 Mn |
| Sep 30, 2021 | 724,000.00 |